Navigation Links
Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
Date:9/9/2012

SEATTLE, Sept. 9, 2012 /PRNewswire/ -- The Heart Failure Society of America (HFSA) 16th Annual Scientific Meeting convened today at the Washington State Convention Center in Seattle. The meeting will feature several satellite sessions this afternoon and tomorrow, which are sponsored by educational grants from several outside supporters of HFSA.

This year's satellite symposia feature several interesting topics, including:

  • The Tao of the Right Ventricle: A Wicked Problem
  • Mechanically Assisted Circulation: Therapeutic Options Across the Spectrum of Advanced Heart Failure
  • The Impact of New Rhythm Device Technology on Patient Management Options
  • Achieving Treatment Success for Patients with Heart Failure Complicated by Hyponatremia
  • Sleep Disordered Breathing in Heart Failure: Challenges and Opportunities
  • Hydralazine and Isosorbide Dinitrate Therapy in Heart Failure: Past, Present and Future

The 16th Annual Scientific Meeting is a four-day forum for heart failure specialists to present research findings and advances in treatment. Presentations will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7193 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may follow news from the meeting on Twitter @HFSA and #HFSA

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.


'/>"/>
SOURCE Heart Failure Society of America
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
2. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
3. First Baby With Artificial Heart in Japan
4. Mending a broken heart -- with a molecule that turns stem cells into heart cells
5. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
6. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
7. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
8. Magnet helps target transplanted iron-loaded cells to key areas of heart
9. Scientists develop new technique that could improve heart attack prediction
10. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
11. Slovenias 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):